share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股SEC公告 ·  08/23 16:13

Moomoo AI 已提取核心訊息

bluebird bio, Inc., a biotechnology company listed on Nasdaq under the ticker symbol BLUE, is facing compliance issues due to delayed financial filings. The company has not filed its Annual Report for 2023 or its Quarterly Reports for Q1 and Q2 of 2024, which has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1). This rule requires timely submission of periodic financial reports. bluebird bio received notification letters from Nasdaq on August 20, 2024, regarding this non-compliance. The company had previously reported the need to restate its consolidated financial statements for 2022 and the first three quarters of 2023, which has contributed to the delay. Nasdaq has granted bluebird bio a compliance period until October 14, 2024, to file the overdue reports and regain compliance. The company plans to...Show More
bluebird bio, Inc., a biotechnology company listed on Nasdaq under the ticker symbol BLUE, is facing compliance issues due to delayed financial filings. The company has not filed its Annual Report for 2023 or its Quarterly Reports for Q1 and Q2 of 2024, which has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1). This rule requires timely submission of periodic financial reports. bluebird bio received notification letters from Nasdaq on August 20, 2024, regarding this non-compliance. The company had previously reported the need to restate its consolidated financial statements for 2022 and the first three quarters of 2023, which has contributed to the delay. Nasdaq has granted bluebird bio a compliance period until October 14, 2024, to file the overdue reports and regain compliance. The company plans to update its Compliance Plan by September 4, 2024, and intends to file the necessary reports as soon as possible. Despite the notices, there is no immediate impact on the trading of bluebird bio's securities on Nasdaq. The company has issued a press release on August 23, 2024, to publicly announce the receipt of the Nasdaq notices.
生物技術公司bluebird bio, Inc.在納斯達克上市,股票代碼爲BLUE,由於延遲提交財務報表而面臨合規問題。該公司尚未提交2023年的年度報告,以及2024年第一季度和第二季度的季度報告,導致未能遵守納斯達克規則5250(c)(1)。該規則要求定期財務報告的及時提交。bluebird bio於2024年8月20日收到納斯達克關於此違規行爲的通知函。該公司此前已報告需要重新調整其2022年和2023年前三個季度的合併財務報表,這是導致延遲的原因。納斯達克已經給予bluebird bio到2024年10月14日提交逾期報告並恢復合規的寬限期。該公司計劃在2024年9月4日之前更新其合規計劃,並打算儘快提交必要的報告。儘管收到通知,但此舉並沒有立即影響bluebird bio在納斯達克上證券的交易。該公司於2024年8月23日發佈新聞稿公開宣佈收到納斯達克通知的消息。
生物技術公司bluebird bio, Inc.在納斯達克上市,股票代碼爲BLUE,由於延遲提交財務報表而面臨合規問題。該公司尚未提交2023年的年度報告,以及2024年第一季度和第二季度的季度報告,導致未能遵守納斯達克規則5250(c)(1)。該規則要求定期財務報告的及時提交。bluebird bio於2024年8月20日收到納斯達克關於此違規行爲的通知函。該公司此前已報告需要重新調整其2022年和2023年前三個季度的合併財務報表,這是導致延遲的原因。納斯達克已經給予bluebird bio到2024年10月14日提交逾期報告並恢復合規的寬限期。該公司計劃在2024年9月4日之前更新其合規計劃,並打算儘快提交必要的報告。儘管收到通知,但此舉並沒有立即影響bluebird bio在納斯達克上證券的交易。該公司於2024年8月23日發佈新聞稿公開宣佈收到納斯達克通知的消息。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息